U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H42O4
Molecular Weight 430.62
Optical Activity UNSPECIFIED
Defined Stereocenters 12 / 12
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RUSCOGENIN

SMILES

[H][C@]12C[C@@]3([H])[C@]4([H])CC=C5C[C@@H](O)C[C@@H](O)[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]1([H])[C@H](C)[C@@]6(CC[C@@H](C)CO6)O2

InChI

InChIKey=QMQIQBOGXYYATH-IDABPMKMSA-N
InChI=1S/C27H42O4/c1-15-7-10-27(30-14-15)16(2)24-22(31-27)13-21-19-6-5-17-11-18(28)12-23(29)26(17,4)20(19)8-9-25(21,24)3/h5,15-16,18-24,28-29H,6-14H2,1-4H3/t15-,16+,18-,19-,20+,21+,22+,23-,24+,25+,26+,27-/m1/s1

HIDE SMILES / InChI
Ruscogenin is a major steroid sapogenin found in the traditional Chinese medicinal herb Ophiopogon japonicus. It was first isolated from Ruscus aculeatus. Ruscogenin has multiple bioactivities and possesses a variety of pharmacological activities: anti-inflammatory properties, platelet aggregation inhibition, pulmonary hypertension lowering properties, acute lung injury alleviation and other effects. It was shown, that ruscogenin inhibited activation of neutrophil through cPLA2, PAK, Akt, MAPKs, cAMP, and PKA signaling pathways. In addition, Ruscogenin decreased expression of genes involved in hepatic lipogenesis through downregulation of NF-κB-mediated inflammatory responses. It was shown that ruscogenin significantly attenuate LPS-induced acute lung injury (ALI) via inhibiting expressions of TF and iNOS and NF-κB p65 activation, indicating it was a potential therapeutic agent for ALI or sepsis.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rats. Human data not available

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

streptozotocin-induced diabetic rat: Two weeks after STZ injection, rats in the treatment group were orally dosed with 0.3, 1.0 or 3.0 mg/kg ruscogenin for 8 weeks. The normal rats were chosen as nondiabetic control group.
Route of Administration: Oral
Ruscogenin displayed potent antioxidative effects against Formyl-Met-Leu-Phe (FMLP)-induced extra- and intracellular superoxide generation in mouse bone marrow neutrophils, with IC50 values of 1.07±0.32 μM and 1.77±0.46 μM, respectively. Phorbol myristate acetate (PMA)-elicited extra- and intracellular superoxide generation were also suppressed by ruscogenin, with IC50 values of 1.56±0.46 μM and 1.29±0.49 μM, respectively. However, ruscogenin showed weak inhibition in NaF-induced response. Inhibition of superoxide generation was mediated neither by a superoxide-scavenging ability nor by a cytotoxic effect.
Name Type Language
RUSCOGENIN
INCI   MART.   WHO-DD  
INCI  
Official Name English
RUSCOGENIN [MART.]
Common Name English
Ruscogenin [WHO-DD]
Common Name English
(25R)-SPIROST-5-ENE-1.BETA.,3.BETA.-DIOL
Common Name English
SPIROST-5-ENE-1,3-DIOL, (1.BETA.,3.BETA.,25R)-
Common Name English
RUSCOGENIN [INCI]
Common Name English
SPIROST-5-ENE-1.BETA.,3.BETA.-DIOL, (25R)-
Common Name English
Code System Code Type Description
PUBCHEM
441893
Created by admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
PRIMARY
FDA UNII
BXI92R2VUJ
Created by admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
PRIMARY
MESH
C012541
Created by admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
PRIMARY
ECHA (EC/EINECS)
207-447-2
Created by admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
PRIMARY
SMS_ID
100000078384
Created by admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
PRIMARY
DAILYMED
BXI92R2VUJ
Created by admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
PRIMARY
EVMPD
SUB15165MIG
Created by admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID401019319
Created by admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
PRIMARY
RXCUI
35890
Created by admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
PRIMARY RxNorm
CAS
472-11-7
Created by admin on Fri Dec 15 19:12:20 GMT 2023 , Edited by admin on Fri Dec 15 19:12:20 GMT 2023
PRIMARY